Page last updated: 2024-12-04

n-palmitoylsphingosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

N-palmitoylsphingosine: structure given in first source; RN given refers to (R*,S*-(E))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-hexadecanoylsphingosine : A N-acylsphingosine in which the ceramide N-acyl group is specified as hexadecanoyl (palmitoyl). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5283564
CHEMBL ID35292
CHEBI ID72959
SCHEMBL ID16027983
SCHEMBL ID10298591
MeSH IDM0256972

Synonyms (57)

Synonym
n-palmitoylsphing-4-enine
n-(hexadecanoyl)sphing-4-enine
n-hexadecanoylsphing-4-enine
n-(hexadecanoyl)ceramide
ceramide (d18:1/16:0)
n-hexadecanoylsphingosine
n-(palmitoyl)ceramide
n-[(2s,3r,4e)-1,3-dihydroxyoctadec-4-en-2-yl]hexadecanamide
BSPBIO_001281
IDI1_033751
n-acylsphingosine ,
n-((e,2s,3r)-1,3-dihydroxyoctadec-4-en-2-yl)palmitamide
cer(d18:1/16:0)
LMSP02010004
n-(hexadecanoyl)-ceramide
c16 cer
n-(hexadecanoyl)-sphing-4-enine
n-(palmitoyl)-ceramide
n-palmitoyl-sphingosine
c16 ceramide
NCGC00161362-01
NCGC00161362-02
n-palmitoylsphingosine
NCGC00161362-03
HMS1989A03
chebi:72959 ,
CHEMBL35292 ,
n-palmitoyl-d-erythro-sphingosine
24696-26-2
BML3-D03
HMS1361A03
HMS1791A03
n-(1,3-dihydroxyoctadec-4-en-2-yl)hexadecanamide
bdbm50289523
hexadecanoic acid ((e)-(1s,2r)-2-hydroxy-1-hydroxymethyl-heptadec-3-enyl)-amide
sphing-4-enine-16-ceramide
c16-ceramide
n-[(e,2s,3r)-1,3-dihydroxyoctadec-4-en-2-yl]hexadecanamide
YDNKGFDKKRUKPY-TURZORIXSA-N
SCHEMBL16027983
SCHEMBL10298591
HMS3402A03
n-palmitoyl-d-sphingosine, >=98.0% (tlc)
c16 ceramide (n-palmitoylsphingosine, d-erythro)
J-015630
ceramide (18:1/16:0)
ceramide d34:1
c16 ceramide (d18:1/16:0), n-palmitoyl-d-erythro-sphingosine, powder
n-[(1s,2r,3e)-2-hydroxy-1-(hydroxymethyl)heptadec-3-en-1-yl]hexadecanamide
hexadecanamide,n-[(1s,2r,3e)-2-hydroxy-1-(hydroxymethyl)-3-heptadecenyl]-
n-palmitoyl-d-erythro-sphingosine;n-hexadecanoyl-d-erythro-sphingosine;n-palmitoyl ceramide
CS-0018668
HY-100354
DTXSID301317974
CUA24306
AKOS040755906
BP-28815

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Mycoplasma genitalium metaboliteAny bacterial metabolite produced during a metabolic reaction in Mycoplasma genitalium.
human blood serum metaboliteAny metabolite (endogenous or exogenous) found in human blood serum samples.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
N-acylsphingosineThe parent compounds of the ceramide family, composed of sphingosine having an unspecified fatty acyl group attached to the nitrogen.
Cer(d34:1)
N-palmitoyl-sphingoid base
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (5)

PathwayProteinsCompounds
Sphingolipid metabolism (integrated pathway)1167
Sphingolipid metabolism: integrated pathway163
16p11.2 proximal deletion syndrome039
Sphingolipid pathway315
Sphingolipids metabolism pathway063

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
regulator of G-protein signaling 4Homo sapiens (human)Potency0.21190.531815.435837.6858AID504845
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency0.14130.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1646808Displacement of fluorescent tagged ceramide from immobilized His-tagged CERT START domain (unknown origin) assessed as reduction in residual fluorescence activity by FLINT assay relative to control2020Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
N,O-Dialkyl deoxynojirimycin derivatives as CERT START domain ligands.
AID401377Toxicity against Ulva conglobata at 50 ppm1998Journal of natural products, Jun-26, Volume: 61, Issue:6
New ceramide from marine sponge Haliclona koremella and related compounds as antifouling substances against macroalgae.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (84)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (5.95)18.2507
2000's30 (35.71)29.6817
2010's36 (42.86)24.3611
2020's13 (15.48)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other84 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]